Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.

Autor: Chon I; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan. Electronic address: irinachon@med.niigata-u.ac.jp., Wagatsuma K; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Saito R; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Tang JW; Respiratory Sciences, University of Leicester, Leicester, UK; Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK., Isamu S; Yoiko Pediatric Clinic, Niigata, Japan., Suzuki E; Suzuki Pediatric Clinic, Yamaguchi, Japan., Shirahige Y; Shirahige Clinic, Nagasaki, Japan., Kawashima T; Kawashima Internal Medicine Clinic, Gunma, Japan., Minato M; Minato Pediatric Clinic, Tokyo, Japan., Kodo N; Kodo Pediatric Clinic, Kyoto, Japan., Masaki H; Masaki Respiratory Medicine Clinic, Nagasaki, Japan., Hamabata H; Awase-Daiichi Clinic, Okinawa, Japan., Yoshioka S; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Ichikawa Y; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Sun Y; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Li J; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Otoguto T; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan., Watanabe H; Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Jazyk: angličtina
Zdroj: Antiviral research [Antiviral Res] 2024 Sep; Vol. 229, pp. 105956. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1016/j.antiviral.2024.105956
Abstrakt: Baloxavir marboxil (baloxavir), approved as an anti-influenza drug in Japan in March 2018, can induce reduced therapeutic effectiveness due to PA protein substitutions. We assessed PA substitutions in clinical samples from influenza-infected children and adults pre- and post-baloxavir treatment, examining their impact on fever and symptom duration. During the 2022-2023 influenza season, the predominant circulating influenza subtype detected by cycling-probe RT-PCR was A(H3N2) (n = 234), with a minor circulation of A(H1N1)pdm09 (n = 10). Of the 234 influenza A(H3N2) viruses collected prior to baloxavir treatment, 2 (0.8%) viruses carry PA/I38T substitution. One virus was collected from a toddler and one from an adult, indicating the presence of viruses with reduced susceptibility to baloxavir, without prior exposure to the drug. Of the 54 paired influenza A(H3N2) viruses collected following baloxavir treatment, 8 (14.8%) viruses carried E23 K/G, or I38 M/T substitutions in PA. Variant calling through next-generation sequencing (NGS) showed varying proportions (6-100 %), a polymorphism and a mixture of PA/E23 K/G, and I38 M/T substitutions in the clinical samples. These eight viruses were obtained from children aged 7-14 years, with a median fever duration of 16.7 h and a median symptom duration of 93.7 h, which were similar to those of the wild type. However, the delayed viral clearance associated with the emergence of PA substitutions was observed. No substitutions conferring resistance to neuraminidase inhibitors were detected in 37 paired samples collected before and following oseltamivir treatment. These findings underscore the need for ongoing antiviral surveillance, informing public health strategies and clinical antiviral recommendations for seasonal influenza.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: